Maliha Akhtar Zubairy*, Fatima Kanani, Soma Vankwani
Dengue virus (DENV) and SARS-CoV-2 are single, positive-stranded RNA viruses infecting humans. The early clinical presentation of both viral diseases is quite similar, creating a serious challenge for healthcare providers to discriminate between the two diseases. Recent studies report cases of co-infection as well as cross-reactivity of DENV and COVID-19. Therefore, a retrospective study was designed to identify cases of co-infection/cross-reactivity and its severity based on Liver Function Tests (LFTs). We identified 38 cases of co-infection in a tertiary care hospital in Karachi, Pakistan during the year 2020. These cases were dengue NS-1 Ag or IgM/ IgG antibody-positive along with SARS-CoV-2 RT-PCR positive. The serological profile of co-infected cases revealed that the pattern of dengue serology is mainly based on IgG positivity followed by IgG & IgM positivity. Whereas, a single case of positive NS-1 and a single case of only IgM positive were found. The finding supports that if it is co-infection then might be more common in secondary as compared to primary dengue infection and not causing severe liver damage. This study strongly suggests, to exclude the possibility of cross-reactivity of antibodies in this pandemic condition, dengue infection should be confirmed by using accurate methods (RT-PCR or Virus isolation). Secondly, this study alarms that the dengue-endemic countries are at a higher risk of misdiagnosis of viral infection. Therefore, precautionary measures by the government agencies should be taken in this pandemic situation to reduce dengue infection in future.
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi